Eternity Bioscience Inc

Palatin Technologies is a biopharmaceutical research and development company with a focus on developing melanocortin-based therapeutics. Additionally, the company has a pipeline of product opportunities in development. The company s internal research and development capability, anchored by its proprietary MIDAS drug-discovery technology platform, is the core of its new product development program. Palatin s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize its commercial potential. The company's flagship proprietary product is Bremelanotide, an intranasally administered melanocortin receptor agonist in development for the treatment of both male and female sexual dysfunction. Palatin Technologies has formed a strategic alliance with King Pharmaceuticals to jointly develop and commercialize Bremelanotide. Palatin Technologies maintains its corporate headquarters in Cranbury, N.J.

Cornerstone Pharmaceuticals, based in Cranbury, NJ, is dedicated to exploring innovative antimetabolic cancer therapies. The company is currently focused on testing its lead drug candidate, CPI-613 (devimistat), in various preclinical models of cancer. With a commitment to advancing cancer treatment, Cornerstone Pharmaceuticals aims to develop effective therapeutic combinations that target metabolic pathways in cancer cells. Their research and development efforts are centered on improving patient outcomes through novel therapeutic strategies. Generated from the website

Wuxi Biologics USA, based in Cranbury, NJ, is a leading global biologics company specializing in contract development and manufacturing services for the biopharmaceutical industry. The company offers a wide range of services, including cell line development, process development, and cGMP manufacturing, to support the development and production of biologic drugs. Generated from their business information